N-(Hydroxyacetyl)glycyl-L-tyrosinamide | 919104-62-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(Hydroxyacetyl)glycyl-L-tyrosinamide
• 英文别名: (2S)-2-[[2-[(2-hydroxyacetyl)amino]acetyl]amino]-3-(4-hydroxyphenyl)propanamide
• CAS: 919104-62-4
• 化学式: C₁₃H₁₇N₃O₅
• 分子量: 295.29
• InChiKey: KNZOJVYRWYJBTP-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  142
• 氢给体数：
  5
• 氢受体数：
  5

文献信息

• N- or C- terminally modified small peptides
  申请人：Larsen Due Bjarne

  公开号：US20070123469A1

  公开（公告）日：2007-05-31

  N- or C-terminally modified small peptides having antiarrhythmic properties are disclosed, and in particular small peptides that possess improved pharmacokinetic properties such as having a reduced tendency to inhibit the activity of isozyme 3A4 of cytochrome P450 oxidase. The invention further relates to uses of said compounds in the preparation of a medicament, and to pharmaceutical compositions comprising said compounds.
• US7585839B2
  申请人：——

  公开号：US7585839B2

  公开（公告）日：2009-09-08
• US7749969B2
  申请人：——

  公开号：US7749969B2

  公开（公告）日：2010-07-06
• [EN] N- OR C- TERMINALLY MODIFIED SMALL PEPTIDES<br/>[FR] PETITS PEPTIDES A TERMINAISON N OU C MODIFIEE
  申请人：ZEALAND PHARMA AS

  公开号：WO2007007060A2

  公开（公告）日：2007-01-18

  [EN] N- or C-terminally modified small peptides having antiarrhythmic properties are disclosed, and in particular to small peptides that possess improved pharmacokinetic properties such as have a reduced tendency to inhibit the activity of isozyme 3A4 of cytochrome P 450 oxidase. The invention further relates to uses of said compounds in the preparation of a medicament, and to pharmaceutical compositions comprising said compounds.
  [FR] L'invention concerne de petits peptides à terminaison N ou C modifiée présentant des propriétés antiarrhythmiques et, en particulier, de petits peptides qui possèdent des propriétés pharmacocinétiques améliorées, telles qu'une tendance limitée à inhiber l'activité de l'isozyme 3A4 de la cytochrome P 450 oxydase. L'invention concerne également les utilisations de ces composés pour préparer un médicament, et des compositions pharmaceutiques comprenant lesdits composés.